AbCellera Biologics (ABCL) vs Arcutis Biotherapeutics (ARQT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AbCellera Biologics (ABCL) has outperformed Arcutis Biotherapeutics (ARQT) over the past year, gaining 176.1% versus a loss of 10.6%. Over five years, ARQT leads with a +58.1% price change compared with -30.7% for ABCL. Arcutis Biotherapeutics is the larger company by market cap ($3.33 billion vs $3.16 billion), about 1.1 times the size, while AbCellera Biologics is growing revenue faster (+160.6% vs +91.3%).
Arcutis Biotherapeutics converts more of its revenue into profit, with a net margin of -4.3% versus -194.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABCL | ARQT |
|---|---|---|
| Share price | $9.69 | $26.36 |
| Market cap | $3.16B | $3.33B |
| 1-day change | -7.45% | -2.98% |
| YTD return | +183.33% | -9.23% |
| 1-year return | +176.07% | -10.61% |
| 5-year return | -30.74% | +58.13% |
| P/E ratio (TTM) | — | 119.82 |
| Forward P/E | — | 24.09 |
| EPS (TTM) | $-0.48 | $0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.13M | $376.07M |
| Revenue growth (YoY) | +160.56% | +91.34% |
| Net income (latest FY) | $-146.41M | $-16.14M |
| Gross margin | — | 90.24% |
| Operating margin | -288.98% | -3.25% |
| Net margin | -194.88% | -4.29% |
| 52-week high | $15.02 | $34.80 |
| 52-week low | $2.75 | $19.30 |
| Distance from 52-week high | -35.46% | -24.25% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +92.67% | +53.19% |
| Average volume | 4.34M | 2.58M |
| Shares outstanding | 326.62M | 126.46M |
| Employees | 562 | 354 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABCL has outperformed ARQT by 186.7 percentage points over the past year.
- Arcutis Biotherapeutics is more profitable, keeping -4.3 cents of every revenue dollar as net income versus -194.9 cents for AbCellera Biologics.
- AbCellera Biologics grew revenue faster in its latest fiscal year (+160.56% vs +91.34%).
About AbCellera Biologics
ABCL stock →AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
ABCL vs ARQT FAQ
Which is bigger, AbCellera Biologics or Arcutis Biotherapeutics?
Arcutis Biotherapeutics (ARQT) is larger, with a market capitalization of $3.33B compared with $3.16B for AbCellera Biologics (ABCL).
Which stock has performed better over the past year, ABCL or ARQT?
ABCL returned +176.07% over the past 12 months, compared with -10.61% for ARQT (price return, excluding dividends). Past performance does not predict future results.
Are AbCellera Biologics and Arcutis Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.